Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated)

For most adults, the standard dose of the vaccine containing the Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen is a single 0.5 mL intramuscular injection. This is typically administered once annually, ideally before the onset of peak influenza activity in the community (usually by the end of October in the Northern Hemisphere).

For adults aged 65 and older, a 'High-Dose' version may be recommended. This version contains 60 mcg of the H3N2 antigen per dose, compared to the 15 mcg found in standard-dose vaccines. This higher concentration is designed to elicit a stronger immune response in older adults whose immune systems may not respond as robustly to standard doses.

Pediatric dosing depends on the age of the child and their previous vaccination history:

• Children 6 months through 8 years: If the child has not received at least two doses of influenza vaccine previously (at any time), they may require two doses of the vaccine containing this antigen, spaced at least 4 weeks apart. This 'prime-boost' strategy ensures the child's immune system is sufficiently prepared. The dose is typically 0.5 mL per injection.
• Children 9 years and older: A single 0.5 mL dose is standard, regardless of previous vaccination history.
• Infants under 6 months: This antigen is NOT approved for use in infants under 6 months of age, as they do not mount an effective immune response and are protected primarily through maternal antibodies (if the mother was vaccinated during pregnancy).

Renal Impairment

No dosage adjustments are required for patients with renal impairment. The antigen is not cleared by the kidneys, and clinical studies have shown the vaccine to be safe in patients with various stages of chronic kidney disease, including those on dialysis.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment. There is no evidence that liver dysfunction affects the safety or efficacy of the inactivated antigen.

Elderly Patients

As noted, elderly patients may receive either the standard dose or the high-dose/adjuvanted versions specifically designed for their age group. The choice should be discussed with a healthcare provider based on the patient's overall health and the specific vaccine brands available.

This medication is administered exclusively by a healthcare professional.

• Route: Intramuscular (IM) injection is the standard route. In adults and older children, the preferred site is the deltoid muscle of the upper arm. In infants and young children, the anterolateral aspect of the thigh is preferred.
• Preparation: The vaccine should be shaken well before administration to ensure a homogenous suspension. It should be inspected visually for particulate matter or discoloration.
• Storage: The vaccine must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It must NEVER be frozen. Exposure to freezing temperatures destroys the integrity of the antigen.
• Co-administration: This vaccine can generally be administered at the same time as other vaccines (e.g., COVID-19, pneumococcal, or shingles vaccines), provided they are given in different anatomical sites (different arms).

Since this is an annual vaccine, a 'missed dose' refers to failing to get vaccinated during the flu season. If you miss the early window (October), you should still receive the vaccine as long as flu viruses are circulating, which can be as late as May or June.

An overdose of an inactivated vaccine is highly unlikely as it is administered in a single-dose pre-filled syringe by a professional. If a double dose were accidentally administered, the primary risk would be an increase in the severity of local injection site reactions (pain, swelling) or systemic symptoms (fever). There is no specific 'antidote' for a vaccine overdose; treatment is supportive (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Side effects from the Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen are generally mild and are a sign that the body is building protection. The most frequently reported issues include:

• Injection Site Pain: This is the most common reaction, occurring in up to 60-80% of recipients. It typically feels like a dull ache in the deltoid muscle and usually resolves within 24 to 48 hours.
• Tenderness and Redness: The area around the injection may be sensitive to touch or appear slightly pink.
• Fatigue: A general feeling of tiredness or lethargy as the immune system activates.
• Headache: Mild to moderate tension-type headaches are common in the first 24 hours after vaccination.

• Myalgia (Muscle Aches): Generalized muscle aches that are not limited to the injection site.
• Arthralgia (Joint Pain): Mild discomfort in the joints.
• Low-Grade Fever: A temperature usually below 101°F (38.3°C). This is more common in children than in adults.
• Nausea: Mild stomach upset or loss of appetite, particularly in pediatric populations.
• Shivering/Chills: Often occurring alongside a low-grade fever.

• Lymphadenopathy: Swelling of the lymph nodes, usually in the armpit (axillary) on the side where the shot was given.
• Urticaria (Hives): A localized or generalized itchy rash.
• Syncope (Fainting): This is usually a vasovagal response to the needle itself rather than a reaction to the antigen, most common in adolescents.

While extremely rare, serious reactions can occur.

> Warning: Stop taking Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the face or throat, rapid heartbeat, dizziness, and a widespread rash. This usually occurs within minutes of the injection.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. The estimated risk is about 1 to 2 additional cases for every million doses of flu vaccine administered.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Severe pain and limited range of motion in the shoulder caused by the needle being injected too high or too deep into the shoulder joint capsule rather than the muscle.
• High Fever: A temperature exceeding 103°F (39.4°C).

There are no known long-term side effects associated with the Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen. The antigen is cleared from the body within days, and the immune response it triggers is a natural biological process. Extensive monitoring by the CDC and FDA via the Vaccine Adverse Event Reporting System (VAERS) has consistently shown that seasonal flu vaccines do not cause long-term health problems.

There are no FDA black box warnings for this antigen. It is considered one of the safest medical interventions available. However, the package insert for vaccines containing this antigen always includes a warning regarding the history of GBS and severe egg allergy.

Report any unusual symptoms to your healthcare provider. If you experience a significant reaction, you or your provider should report it to VAERS at https://vaers.hhs.gov.

Before receiving a vaccine containing the Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen, it is vital to disclose your full medical history to your healthcare provider. While generally safe, certain conditions may require a delay in vaccination or a specific type of flu vaccine formulation.

No FDA black box warnings for Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of severe, life-threatening allergies to any component of the vaccine (including formaldehyde, which is used in the inactivation process, or antibiotics like neomycin used to prevent bacterial growth during manufacturing) should not receive this specific vaccine.
• Egg Allergy: Because the IVR-221 strain is often grown in embryonated chicken eggs, the final product may contain trace amounts of ovalbumin (egg protein). While most people with egg allergies can safely receive the flu vaccine, those with a history of severe egg allergy (anaphylaxis) should be vaccinated in a medical setting where an allergic reaction can be recognized and managed.
• Guillain-Barré Syndrome (GBS): If you have ever had GBS within 6 weeks of a previous influenza vaccination, your doctor will carefully weigh the risks and benefits before administering another flu vaccine.
• Moderate to Severe Acute Illness: If you have a significant illness with a fever, vaccination is usually deferred until the symptoms resolve. This is to avoid diagnostic confusion between the symptoms of the illness and potential side effects of the vaccine. A mild 'cold' or slight sniffle is not a reason to delay vaccination.
• Immunocompromised Patients: While the vaccine is safe for immunocompromised individuals (because it is inactivated and cannot cause infection), the immune response may be weaker than in healthy individuals. These patients may still be at risk for flu even after vaccination.

There are no routine lab tests (like blood counts or liver function tests) required before or after receiving this antigen. However, healthcare providers typically monitor patients for 15 minutes after the injection to ensure no immediate allergic reactions or fainting (syncope) occur.

The Influenza A H3N2 antigen has no known effect on the ability to drive or operate heavy machinery. If you feel dizzy or faint immediately after the injection, you should wait until the feeling passes before driving.

There is no direct interaction between alcohol and the Influenza A H3N2 antigen. However, excessive alcohol consumption can suppress the immune system, potentially reducing the effectiveness of the vaccine. It is best to avoid heavy drinking around the time of vaccination.

As this is a single-dose annual intervention, 'discontinuation' is not applicable in the way it is for daily medications. However, if a patient has a severe reaction to the H3N2 component, they should not receive that specific formulation in future years and should discuss alternative vaccines (like cell-based or recombinant vaccines) with their allergist.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would prevent the use of the Influenza A H3N2 antigen. However, it should not be mixed in the same syringe with any other vaccine or medication.

• Immunosuppressive Therapies: Drugs that suppress the immune system can significantly reduce the body's ability to respond to the H3N2 antigen. This includes:
• High-dose Corticosteroids: (e.g., Prednisone >20mg/day for more than 2 weeks).
• Chemotherapy: Cytotoxic agents used for cancer treatment.
• Biologics: TNF-inhibitors (e.g., adalimumab, etanercept) and B-cell depleting agents (e.g., rituximab).
• Management: If possible, vaccination should be timed to occur when the patient is at their highest level of immunocompetence (e.g., between chemo cycles).

• Antiviral Medications: While neuraminidase inhibitors like oseltamivir (Tamiflu) do not interfere with inactivated vaccines, they can interfere with live attenuated influenza vaccines (LAIV). For the formaldehyde-inactivated antigen, there is no known interaction, but some clinicians prefer a 48-hour gap between antiviral use and vaccination.
• Anticoagulants: In patients taking warfarin, heparin, or NOACs (e.g., apixaban), the risk of a hematoma (deep bruise) at the injection site is increased. A fine-gauge needle should be used, and firm pressure applied for at least 2 minutes post-injection.

There are no known interactions with food, including grapefruit, dairy, or caffeine. The antigen's efficacy is not affected by diet.

There is limited data on herbal interactions. However, some supplements known to modulate the immune system (like high-dose echinacea or elderberry) are often used by patients during flu season. There is no evidence that these interfere with the H3N2 antigen's ability to produce antibodies.

• False Positive Serology: Following flu vaccination, there have been rare reports of transient false-positive results in serology tests for HIV-1, Hepatitis C, and HTLV-1. These are due to the production of IgM antibodies that cross-react in certain ELISA assays. If a positive result occurs shortly after vaccination, a more specific confirmatory test (like a Western Blot or PCR) should be performed.
• HI Titers: The vaccine will, by design, increase the Hemagglutination Inhibition (HI) titers for the H3N2 strain. This is a sign of vaccine efficacy, not a negative lab interaction.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Allergic Reaction (Anaphylaxis): Anyone who has had a documented life-threatening allergic reaction to a previous dose of any influenza vaccine or to any specific component of this vaccine (including formaldehyde, egg protein, or trace antibiotics) must not receive it. The mechanism is an IgE-mediated hypersensitivity that could lead to airway obstruction or cardiovascular collapse upon re-exposure.
• Infants under 6 Months: The safety and efficacy of the H3N2 antigen have not been established in this age group. Their immune systems are too immature to respond to the antigen, and the risk-benefit ratio is unfavorable.

• History of Guillain-Barré Syndrome (GBS): A history of GBS within 6 weeks of a previous flu shot is a relative contraindication. Doctors will evaluate if the risk of flu complications (which can also trigger GBS) outweighs the very small risk of vaccine-triggered recurrence.
• Acute Febrile Illness: Vaccination should be delayed until the fever has subsided to ensure that any potential vaccine side effects are not confused with the progression of the underlying illness.

• Formaldehyde Sensitivity: Since formaldehyde is used to inactivate the virus, trace amounts may remain. Individuals with known contact dermatitis to formaldehyde should be monitored, though the amount in the vaccine is typically much lower than what is found naturally in the human body.
• Neomycin/Polymyxin Sensitivity: Some manufacturing processes use these antibiotics to prevent contamination. Patients with systemic (not just skin) allergies to these antibiotics should exercise caution.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated).

FDA Pregnancy Category: B/C (varies by specific brand).

Extensive clinical data and observational studies have shown that inactivated influenza vaccines are safe to administer during any trimester of pregnancy. In fact, the CDC and ACOG (American College of Obstetricians and Gynecologists) strongly recommend it.

• Maternal Benefit: Pregnant women are at significantly higher risk for severe complications from H3N2 influenza due to changes in their immune, heart, and lung systems.
• Fetal Benefit: Antibodies produced by the mother cross the placenta and provide critical protection to the newborn for the first several months of life, a period when the infant is too young to be vaccinated themselves.

Inactivated influenza antigens like Tasmania/503/2020 (H3N2) do not pass into breast milk in a way that would affect the infant. Breastfeeding is not a contraindication. In fact, breastfeeding mothers who are vaccinated may pass protective antibodies (IgA) to their infants through breast milk, further reducing the infant's risk of respiratory infections.

Approved for children 6 months and older. As noted in the dosage section, young children may require two doses. The H3N2 component is particularly important for children, as this subtype is often associated with higher rates of pediatric hospitalization compared to Influenza B strains.

Adults 65 and older are at the highest risk for H3N2-related mortality. While the standard dose is safe, this population often experiences 'immunosenescence,' where the antibody response is less robust. Consequently, the use of high-dose or adjuvanted vaccines containing this antigen is preferred to ensure adequate protection.

Patients with renal failure or those on dialysis can safely receive this antigen. Their immune response may be slightly diminished compared to healthy peers, but the safety profile remains excellent. No dose adjustment is needed.

There are no specific concerns for patients with liver disease. The antigen is processed by the immune system, not the liver's cytochrome P450 system. It is safe for patients with cirrhosis or hepatitis.

> Important: Special populations require individualized medical assessment.

Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated) functions as an immunogenic stimulus. The primary molecular target is the Hemagglutinin (HA) protein. In a natural infection, the HA protein binds to sialic acid receptors on the surface of human respiratory epithelial cells, allowing the virus to enter. The vaccine-induced antibodies bind to the 'head' region of the HA protein, sterically hindering the virus's ability to attach to host cells. This 'neutralization' prevents the initiation of the viral life cycle.

• Onset of Effect: Antibody levels begin to rise within 7 days of vaccination, but peak protection (seroconversion) typically takes 14 to 21 days.
• Duration of Effect: Protection generally lasts for the duration of one flu season (6 to 8 months). Antibody titers naturally decline over time, which, combined with the 'antigenic drift' of the virus, necessitates annual revaccination.
• Tolerance: There is no pharmacological tolerance; however, 'original antigenic sin' is a theoretical concept where the body's first exposure to a flu strain shapes all future responses to related strains.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular) |

| Protein Binding | N/A |

| Half-life | Antigen cleared in <7 days; Antibodies last 6-12 months |

| Tmax (Antibody) | 2-3 weeks |

| Metabolism | Cellular Proteolysis |

| Excretion | Cellular clearance |

The antigen consists of purified viral subunits. The virus is grown in eggs, harvested, and then disrupted using detergents (like Triton X-100) to create a 'split virus' or 'subunit' vaccine. Formaldehyde is used at a concentration of approximately 100 mcg/mL during the inactivation phase and is largely removed during subsequent purification, leaving only trace amounts (<10 mcg) in the final 0.5 mL dose.

Classified as a Viral Vaccine Antigen. It belongs to the broader group of inactivated (killed) vaccines, which are safer for immunocompromised patients than live vaccines because they contain no genetic material capable of replication.